AtheroGenics, Inc. (NASDAQ: AGIX), a pharmaceutical company focused on the treatment of chronic inflammatory diseases, announced that The Lancet, a peer-reviewed medical journal, will publish an article entitled, “Effects of succinobucol (AGI-1067) after an acute coronary syndrome: a randomized, double-blind, placebo-controlled trial,” in this week’s May 24, 2008 issue.